These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36433678)

  • 21. Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
    Norby FL; Alonso A
    J Comp Eff Res; 2017 Sep; 6(6):549-560. PubMed ID: 28737102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct oral anticoagulants versus warfarin in nonvalvular atrial fibrillation patients with prior gastrointestinal bleeding: a network meta-analysis of real-world data.
    Hu W; Cai H; Zhang J
    Eur J Clin Pharmacol; 2022 Jul; 78(7):1057-1067. PubMed ID: 35296907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
    Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
    Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
    López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
    BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
    [No Abstract]   [Full Text] [Related]  

  • 25. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.
    Escobar C; Martí-Almor J; Pérez Cabeza A; Martínez-Zapata MJ
    Rev Esp Cardiol (Engl Ed); 2019 Apr; 72(4):305-316. PubMed ID: 29606361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
    Lopes RD; Steffel J; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Hamilton M; Friend K; Gupta K; Mardekian J; Pan X; Baser O; Jones WS
    Am J Med; 2018 Sep; 131(9):1075-1085.e4. PubMed ID: 29807001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in anticoagulant prescribing: a review of local policies in English primary care.
    Ho KH; van Hove M; Leng G
    BMC Health Serv Res; 2020 Apr; 20(1):279. PubMed ID: 32245380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies.
    Archontakis-Barakakis P; Li W; Kalaitzoglou D; Tzelves L; Manolopoulos A; Giannopoulos S; Giamouzis G; Giannakoulas G; Batsidis A; Palaiodimos L; Ntaios G; Lip GYH; Kokkinidis DG
    Br J Clin Pharmacol; 2022 Nov; 88(11):4663-4675. PubMed ID: 35853612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
    Deitelzweig S; Farmer C; Luo X; Vo L; Li X; Hamilton M; Horblyuk R; Ashaye A
    Curr Med Res Opin; 2017 Sep; 33(9):1583-1594. PubMed ID: 28644048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry.
    Esteve-Pastor MA; Rivera-Caravaca JM; Ruiz-Ortiz M; Muñiz J; Roldán-Rabadán I; Otero D; López-Gálvez R; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
    Expert Opin Pharmacother; 2022 Aug; 23(12):1457-1465. PubMed ID: 35924672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
    Alamneh EA; Chalmers L; Bereznicki LR
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):183-200. PubMed ID: 26862063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
    Morimoto T; Crawford B; Wada K; Ueda S
    J Cardiol; 2015 Dec; 66(6):466-74. PubMed ID: 26162944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 36. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 37. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
    Alcocer L
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants.
    Cohen AT; Hill NR; Luo X; Masseria C; Abariga SA; Ashaye AO
    Int J Cardiol; 2018 Oct; 269():174-181. PubMed ID: 30037626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.